"Designing Growth Strategies is in our DNA"

Diabetic Neuropathy Market Size, Share And Global Trend By Type (Peripheral, Proximal, Autonomic, Focal), By Drug Class (Non-steroidal Anti-inflammatory Drugs, Antisiezure Drugs, Opioid Drugs, Anti-depressants), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And Geography Forecast Till 2026

Region : Global | Published Date: Ongoing | Report ID: FBI100598| Status : Upcoming



Diabetic neuropathy has been classified into four types peripheral, autonomic, focal, and proximal. The National Institute of Diabetes and Digestive and Kidney Diseases reports that 60% to 70% of people with either type 1 diabetes or type 2 diabetes are likely to suffer from one of the neuropathy types. An estimated 20 million people in the U.S. have some form of peripheral neuropathy and 23% of neuropathy patients are diagnosed with idiopathic neuropathy, or neuropathy coming from an unknown cause. According to an article published by The Foundation for Peripheral Neuropathy in March 2018, studies were conducted by the Indiana University Bloomington in collaboration with the Turku Center for Biotechnology Finland. According to these studies conducted by researchers, there is a correlation between the formation of a certain protein in the cell (NOS1AP) and the transmission of neurological pain. By disrupting the formation of the protein and the resultant biological pathway, pain can be reduced.

The increasing prevalence of diabetes globally is expected to present a large pool of neuropathy patients and subsequently is anticipated to drive the growth of the global diabetic neuropathy market. In addition, the factors like sedentary lifestyle, urbanization and changing genetic composition resulting in the increasing prevalence of obesity and numerous cardiovascular diseases are projected to drive the growth of the global diabetic neuropathy market during 2019-2026. Recently, the National Institute of Neurological Disorders and Stroke (NINDS) provided funds for research activities on neuropathy. Additionally, several Non-Profit organizations in the developing countries are contributing towards the diabetes control. These initiatives are anticipated to drive the growth of the global diabetic neuropathy market during the forecast period.

To get information on various segments, share your queries with us

However, the high cost of diabetic neuropathy drugs is one of the major factor restraining the growth of the global diabetic neuropathy market. Additionally, side effects with the diabetic neuropathy treatment options and lack of absolute treatment and lack of awareness among the patients are anticipated to hamper the growth of the global diabetic neuropathy market.

Key Players Covered

Some of the major companies that are present in the global diabetic neuropathy market are Pfizer Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Akorn, Incorporated, Abbott, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, LUPIN, Glenmark Pharmaceuticals Limited, Assertio Therapeutics, Inc. and Astellas Pharma Inc.  and other players.




By Type

·      Peripheral

·      Proximal

·      Autonomic

·      Focal

By Drug Class

·      Non-steroidal Anti-inflammatory Drugs (NSAIDs)

·      Antisiezure Drugs

·      Opioid Drugs

·       Anti-depressants

·      Others

By Distribution Channel

·      Hospital Pharmacies

·      Retail Pharmacies

·      Online Pharmacies

By Geography

·      North America (USA and Canada)

·      Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

·      Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

·      Latin America (Brazil, Mexico and Rest of Latin America)

·      Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)


Among drug class, non-steroidal anti-inflammatory drugs segment dominated the global diabetic neuropathy market in 2018. The opioid drugs segment is projected to register comparatively higher CAGR durinig forecast period, owing to increasing number of regulatory approvals for opioid medications, combined with new routes of administration for these medications. 

Key Insights

Pipeline Analysis, Key Players

Regulatory Scenario For Key Countries

Prevalence of Diabetic Neuropathy By Key Regions.

Key Industry Developments

Advancements in Research & Development in Diabetic Neuropathy

Regional Analysis

The global diabetic neuropathy market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the largest share in the diabetic neuropathy market in 2018. Increasing prevalence of diabetes and various ongoing R&D initiatives for the development of new treatment options are some of the factors driving the growth of the diabetic neuropathy market in North America. Asia Pacific is anticipated to grow at a significant CAGR during the forecast period due to the increasing prevalence of diabetes and associated comorbidities and increasing awareness towards diagnosis and treatment of diabetic neuropathy.

Key Industry Developments

  • In September 2018, Endexx Corporation, a company dealing in the production of innovative phytonutrient-based food and nutritional products, announced the investment in EcoHealth Neuropathy, Inc. for the launch of its clinical and technology driven management of neuropathies such as diabetic neuropathy.
  • In October 2017, the Food and Drug Administration (DFA), announced the approval of pregabalin extended-release tablets CV for a once daily therapy for the pain associated with peripheral diabetic neuropathy. The product offering was from Pfizer, Inc.
  •  In February 2015, Daiichi Sankyo Company, Limited announced the Phase 3 enrolment for mirogabalin, a gabapentinoid with the developmental code of DS-5565 for the management of diabetic peripheral neuropathic pain

Diabetic Neuropathy Market  Size, Share and Global Industry Trend Forecast till 2026
  • PDF
  • 2018
  • 2014-2017


  • 4850

Healthcare Clients


Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.